CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?
Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.
Healthcare consultant Jared Wolff is joined by Bruna Favetta who has experience with the development of patent strategy, and Kate Jones who has a background in law.
AMARIN has recently found themselves in unchartered territory as VASCEPA’s drug patent is being challenged by generic producers, this episode explores:
- Why this case of VASCEPA is significant
- How this may set a future precedent in drug patent law